Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
4D Molecular Therapeutics ( (FDMT) ) just unveiled an update.
On November 17, 2025, 4D Molecular Therapeutics, Inc. appointed Kristian Humer as Chief Financial Officer and Principal Financial Officer. Mr. Humer brings extensive experience from his previous roles at Foghorn Therapeutics, Viridian Therapeutics, and Citigroup Global Markets. His compensation package includes a base salary of $520,000, a performance bonus, stock options, and a sign-on bonus. The offer includes severance benefits and conditions tied to a change in control, with no disclosed family or transactional ties affecting his appointment.
The most recent analyst rating on (FDMT) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on 4D Molecular Therapeutics stock, see the FDMT Stock Forecast page.
Spark’s Take on FDMT Stock
According to Spark, TipRanks’ AI Analyst, FDMT is a Neutral.
The overall stock score reflects significant financial challenges, with negative income and cash flow trends being major concerns. However, the technical analysis shows positive momentum, which provides some optimism. The valuation remains a concern due to the negative P/E ratio and lack of dividends, highlighting the speculative nature of this investment.
To see Spark’s full report on FDMT stock, click here.
More about 4D Molecular Therapeutics
Average Trading Volume: 802,199
Technical Sentiment Signal: Buy
Current Market Cap: $616.5M
See more insights into FDMT stock on TipRanks’ Stock Analysis page.